Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung Disease

NCT05327803 is registered in ClinicalTrials.gov with AN2 Therapeutics, Inc as lead sponsor.

NCT NCT05327803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05327803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung Disease
Lead sponsor
AN2 Therapeutics, Inc
Phase
Phase 2/3
Overall status
Terminated
Start date
May 20, 2022
Completion date
December 18, 2024
Enrollment
177 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

mac lung disease, treatment refractory mac lung disease